Asco 2022 – Merck’s follow-on immuno-oncology plan hits a myositis problem
ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
Looking beyond Roche’s Tigit bombshell
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
A year of Tigit (and Alzheimer’s) for Roche
With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Scholar Rock’s quest for a better TGF-β drug
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Days of reckoning for immune checkpoint blockers
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Agenus investors wake up to inevitability
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Vantage Esmo 2021 roundup
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.
